CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SECURE aims to develop a self-adaptive gene therapy platform that activates only in response to disease conditions, specifically targeting Parkinson’s Disease. By utilizing synthetic gene circuits and AI-guided design, the project focuses on creating precision therapies that enhance safety and efficacy while personaliz…
What if gene therapy could think, adapt, and act only when needed? SECURE sets out to create the world’s first self-adaptive gene therapy platform ‒ a transformative leap from today’s static interventions toward programmable, intelligent therapeutics.
Rather than permanently active vectors, our approach uses synthetic gene circuits that remain dormant under healthy conditions and activate only in cells exhibiting disease-induced molecular stress.
This ""on-demand"" precision therapy promises unp…
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Israel, Tel Aviv
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Oxford
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Luxembourg, ESCH-SUR-ALZETTE
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, Cardiff
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
